A new FDA approval in heme/onc. Does it matter for your patients? Set up OncoPulse once and the approvals in the cancers you treat come to your inbox. Free.
@meducationai.bsky.social
@meducationai.bsky.socialA new FDA approval in heme/onc. Does it matter for your patients? Set up OncoPulse once and the approvals in the cancers you treat come to your inbox. Free.
@gmj-georgia.bsky.socialA new AI framework teaches neural networks to recognise when they encounter unfamiliar cancer subtypes—preventing overconfident mi… #Artificialintelligence #Cancerdiagnosis #MedicalAI #Oncology #Uncertaintyquantification #Artificialintelligence #Cancerdiagnosis #MedicalAI #Oncology #Uncertainty…
@onclive.bsky.social📰 The Guardant360 CDx has received EU approval as a companion diagnostic to identify patients with ER+, HER2– locally advanced or metastatic breast cancer who may benefit from camizestrant. #bcsm #oncology
Full story ➡️: www.onclive.com/view/guardan...
@onclive.bsky.socialHow are experts navigating subcutaneous therapy administrations in multiple myeloma? Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, break down newer patient-centric approaches #mmsm #oncology
Listen now: www.onclive.com/view/navigat...
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology
@newsramp.comOnco-Innovations (ONCO) is advancing ONC010 toward first-in-human trials, completing a high-purity drug batch, progressing preclinical studies and aligning regulatory planning for a potential Phase I study. #Oncology #Biotech
@newsramp.comOnco-Innovations (ONCO) is advancing ONC010 toward first-in-human trials, completing a high-purity drug batch, progressing preclinical studies and aligning regulatory planning for a potential Phase I study. #Oncology #Biotech
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) debuts on U.S. markets with its precision 'AND-gated' BiTAC cancer platform, early preclinical proof of concept, $27.5M in financing, and two key executive hires. A Swiss biotech to watch. #Oncology #Biotech
@newsramp.comLantern Pharma (NASDAQ: LTRN) receives USPTO Notice of Allowance for LP-284 blood cancer treatment patent, extending IP protection through 2042. The AI-developed therapy targets mantle cell lymphoma and double-hit lymphoma. #Oncology #Biotech
@newsramp.comLantern Pharma (NASDAQ: LTRN) receives USPTO Notice of Allowance for LP-284 blood cancer treatment patent, extending IP protection through 2042. The AI-developed therapy targets mantle cell lymphoma and double-hit lymphoma. #Oncology #Biotech
@newsramp.comTransCode Therapeutics (NASDAQ: RNAZ) expands its global patent portfolio with new IP grants in Australia and Japan covering RNA-based nanoparticle therapies targeting multiple cancers, including breast, lung, and pancreatic. #Oncology #RNATherapeutics
@newsramp.comTransCode Therapeutics (NASDAQ: RNAZ) expands its global patent portfolio with new IP grants in Australia and Japan covering RNA-based nanoparticle therapies targeting multiple cancers, including breast, lung, and pancreatic. #Oncology #RNATherapeutics
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) is advancing its 'AND-gated' BiTAC cancer platform following its NASDAQ debut in June 2026. Early preclinical data and key leadership hires signal the Swiss biotech is gaining momentum in oncology drug development. #Oncology #Biotech
@newsramp.comKairos Pharma (NYSE: KAPA) CSO Neil Bhowmick will present KROS-101 solid tumor research and moderate a cancer drug resistance session at the Discovery on Target Conference in Boston, Sept. 30. #Oncology #BioTech
@newsramp.comKairos Pharma (NYSE: KAPA) CSO Neil Bhowmick will present KROS-101 solid tumor research and moderate a cancer drug resistance session at the Discovery on Target Conference in Boston, Sept. 30. #Oncology #BioTech
@newsramp.comOnco-Innovations and Redwood AI have secured a Terry Fox Research Institute Digital Health Innovation Fund grant to advance their SynoGraph AI oncology platform, backed by a $3.5M project budget. #Oncology #AI
@newsramp.comOnco-Innovations and Redwood AI have secured a Terry Fox Research Institute Digital Health Innovation Fund grant to advance their SynoGraph AI oncology platform, backed by a $3.5M project budget. #Oncology #AI
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) is advancing its oncology pipeline and securing industry partnerships after its Nasdaq debut. Parent company Xlife Sciences reports strong H1 progress across a portfolio backed by 416 patents. #Biotech #Oncology
@newsramp.comCancer treatment is growing more complex as personalized therapies and immunotherapies reshape patient care. Each patient's journey is becoming increasingly unique, demanding greater precision from oncologists and care teams alike. #CancerCare #Oncology
